Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-AV-1451 PET Imaging in Subacute TBI
NCT02512029Phase 1Withdrawn
- Sponsor
- Avid Radiopharmaceuticals
- Start
- Oct 2015
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of flortaucipir in traumatic brain injury (TBI) (2 arms), sponsored by Avid Radiopharmaceuticals. Primary endpoints: TBI Biomarker Analysis, Relationship Between Clinical Presentation and Tau Deposition (MMSE) and 2 more. Planned start Oct 2015; status: withdrawn.
02
Drugs
flortaucipir
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT02512029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02512029.